Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
Julphar
US Department of Justice
Daiichi Sankyo
Harvard Business School
QuintilesIMS
Teva
Cipla
McKesson

Generated: December 15, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.9%

« Back to Dashboard

Clinical Trials for Heparin Sodium 5,000 Units In Sodium Chloride 0.9%

Trial ID Title Status Sponsor Phase Summary
NCT00000468 Myocardial Infarction Triage and Intervention Project (MITI) Completed National Heart, Lung, and Blood Institute (NHLBI) Phase 3 To determine the practicality, benefit, and safety of paramedic administration of thrombolytic therapy for acute myocardial infarction. The feasibility of paramedics correctly identifying candidates for thrombolytic therapy following myocardial infarction was assessed in Phase I. In Phase II, pre-hospital thrombolytic therapy was compared with in-hospital thrombolytic therapy.
NCT00000468 Myocardial Infarction Triage and Intervention Project (MITI) Completed University of Washington Phase 3 To determine the practicality, benefit, and safety of paramedic administration of thrombolytic therapy for acute myocardial infarction. The feasibility of paramedics correctly identifying candidates for thrombolytic therapy following myocardial infarction was assessed in Phase I. In Phase II, pre-hospital thrombolytic therapy was compared with in-hospital thrombolytic therapy.
NCT00182143 PROphylaxis for ThromboEmbolism in Critical Care Trial (PROTECT) Completed Australian and New Zealand Intensive Care Society Clinical Trials Group Phase 3 The purpose of this study is to evaluate the effect of Low Molecular Weight Heparin (LMWH) (Fragmin, dalteparin) versus Unfractionated Heparin (UFH) on the primary outcome of proximal leg Deep Vein Thrombosis (DVT) diagnosed by compression ultrasound, and the secondary outcomes of Pulmonary Embolism (PE), bleeding, Heparin-Induced Thrombocytopenia (HIT), and objectively confirmed venous thrombosis at any site.
NCT00182143 PROphylaxis for ThromboEmbolism in Critical Care Trial (PROTECT) Completed Canadian Critical Care Trials Group Phase 3 The purpose of this study is to evaluate the effect of Low Molecular Weight Heparin (LMWH) (Fragmin, dalteparin) versus Unfractionated Heparin (UFH) on the primary outcome of proximal leg Deep Vein Thrombosis (DVT) diagnosed by compression ultrasound, and the secondary outcomes of Pulmonary Embolism (PE), bleeding, Heparin-Induced Thrombocytopenia (HIT), and objectively confirmed venous thrombosis at any site.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Heparin Sodium 5,000 Units In Sodium Chloride 0.9%

Condition Name

Condition Name for Heparin Sodium 5,000 Units In Sodium Chloride 0.9%
Intervention Trials
Myocardial Infarction 4
Thrombosis 4
Obesity 3
Healthy 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Heparin Sodium 5,000 Units In Sodium Chloride 0.9%
Intervention Trials
Thrombosis 10
Venous Thrombosis 7
Thromboembolism 5
Renal Insufficiency 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Heparin Sodium 5,000 Units In Sodium Chloride 0.9%

Trials by Country

Trials by Country for Heparin Sodium 5,000 Units In Sodium Chloride 0.9%
Location Trials
United States 39
Canada 14
Germany 11
Italy 10
Spain 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Heparin Sodium 5,000 Units In Sodium Chloride 0.9%
Location Trials
Texas 5
California 5
New York 5
Ohio 3
Kansas 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Heparin Sodium 5,000 Units In Sodium Chloride 0.9%

Clinical Trial Phase

Clinical Trial Phase for Heparin Sodium 5,000 Units In Sodium Chloride 0.9%
Clinical Trial Phase Trials
Phase 4 21
Phase 3 11
Phase 2/Phase 3 3
[disabled in preview] 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Heparin Sodium 5,000 Units In Sodium Chloride 0.9%
Clinical Trial Phase Trials
Completed 30
Recruiting 11
Unknown status 8
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Heparin Sodium 5,000 Units In Sodium Chloride 0.9%

Sponsor Name

Sponsor Name for Heparin Sodium 5,000 Units In Sodium Chloride 0.9%
Sponsor Trials
Azidus Brasil 4
GlaxoSmithKline 4
Ain Shams University 3
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Heparin Sodium 5,000 Units In Sodium Chloride 0.9%
Sponsor Trials
Other 89
Industry 28
NIH 5
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
Medtronic
Queensland Health
Cerilliant
Fuji
Colorcon
Boehringer Ingelheim
Cantor Fitzgerald
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.